Arcus Biosciences Inc. (RCUS)
NYSE · Healthcare
Arcus Biosciences Inc. EBITDA 2017–2025
Arcus Biosciences Inc. annual/quarterly ebitda history and growth rate from 2017 to 2026. EBITDA stands for Earnings Before Interest, Taxes, Depreciation and Amortization. It is widely used as a measure of core operational profitability.
- Arcus Biosciences Inc. ebitda for the quarter ending March 31, 2026 was -132.0 M, a 10.92% increase year-over-year.
- Arcus Biosciences Inc. ebitda for the twelve months ending March 31, 2026 was -348.0 M, a 85.15% increase year-over-year.
- Arcus Biosciences Inc. annual ebitda for 2025 was -376.0 M, a 17.50% increase from 2024.
- Arcus Biosciences Inc. annual ebitda for 2024 was -320.0 M, a 3.61% decrease from 2023.
- Arcus Biosciences Inc. annual ebitda for 2023 was -332.0 M, a 21.17% increase from 2022.
- Arcus Biosciences Inc. annual ebitda for 2022 was -274.0 M.
EBITDA
TRAILING 12 MONTHS · $B
QUARTERLY · $B
YEAR-OVER-YEAR GROWTH · %
Arcus Biosciences Inc. EBITDA — FAQ
Arcus Biosciences Inc. (RCUS) ebitda over the last 9 years — annual and quarterly figures with year-over-year growth and charts.
Where can I see RCUS's ebitda history?
The chart and table above show Arcus Biosciences Inc.'s ebitda by year and by quarter, including the growth rate.